Released Jun 15, 2026, after the close
10-Q filed Jun 15, 2026, 46 days after period end · 0001654954-26-005986
Q2 2026 · 10-Q
Revenue$2.70M$2.70M +11.8% vs Q2 2025+17.8% vs Q1 2026
Net Income$232.99K$232.99K +144.3% vs Q2 2025+609.0% vs Q1 2026
EPS Diluted$0.01$0.01 +150.0% vs Q2 2025+900.0% vs Q1 2026
Gross Profit$902,041+10.2%
Operating Income$144,676N/M
Operating Cash Flow-$365,311N/M
Free Cash Flowderived-$367,632N/M
Margins · derived
Gross margin33.4%−0.5 pt vs Q2 2025
Operating margin5.4%+9.4 pt vs Q2 2025
Net margin8.6%+4.7 pt vs Q2 2025
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $2.70M | $2.42M | $2.38M | $4.56M |
| Net Income | $232.99K | $95.35K | -$213.82K | $404.65K |
| EPS Diluted | $0.01 | $0.00 | -$0.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR